| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2016 | Etb067 | H-89 analog as PKA and AKT1 inhibitor with specificity on no longer inhibiting CAMK2B and neither affecting viability of mice nor causing any detectable tissuedamage at the dose given |
|
| DCC2017 | Etc-131 | Novel inhibitor of PORCN, inhibiting ß-catenin reporter activity in a dose-dependent manner |
|
| DCC2018 | Ethd-1 | Cell-impermeant viability indicator, as high-affinity nucleic acid stain that is weakly fluorescent until bound to DNA and emits red fluorescence (excitation/emission maxima ~528/617). |
|
| DCC2019 | Etheofazine | Novel anticancer agent |
|
| DCC2020 | Ethyl 3-hydroxyhexanoate | Natural potent antiviral agent, significantly inhibiting coxsackievirus group B (CVB) replication both in vivo and in vitro |
|
| DCC2021 | Ethyl Lipotf | Novel selective FTO inhibitor |
|
| DCC2022 | Ethylvanillin | TRPA1 channel agonist |
|
| DCC2023 | Etifoxine | Activator of β2 and β3 subunit containing channels of the GABAA receptor complex, stimulating the production of GABA(A) active neurosteroids |
|
| DCC2024 | Et-kuq | Novel enhancer of the religation reaction of human topoisomerase I |
|
| DCC2025 | et-nhp5g | Partial agonist at the glutamate binding site of the GluN2 subunits |
|
| DCC2026 | Etoxazole | Pesticide, acting as antibiotics or growth regulators to kill mites and ticks |
|
| DCC2027 | etp-45299 | Potent and selective inhibitor of Pim 1, inhibiting the phosphorylation of Bad and 4EBP1 in cells and suppresses the proliferation of several non-solid and solid human tumor cell lines. |
|
| DCC2028 | Etx2514 | Novel broad-spectrum β-lactamase inhibitor |
|
| DCC2029 | Eu1622-14 | Novel Biased modulator of NMDA receptors, controlling channel opening and ion selectivity |
|
| DCC2030 | Eu1794-4 | Novel negative allosteric modulator (NAM) of NMDA receptors, reducing both the overall current that flows following receptor activation and the flux of Ca2+ ion relative to monovalent cations |
|
| DCC2031 | Euk-124 | Scavenger for oxidative species such as peroxynitrite, superoxide, and hydrogen peroxide |
|
| DCC2032 | Evolidine | The first plant cyclic peptide with antibacterial and antifungal activity |
|
| DCC2033 | Evp-0015962 | Novel potent gamma-secretase modulator |
|
| DCC2034 | Evt-101 | Novel GluN2B antagonist, binding at the same GluN1/GluN2B dimer interface as ifenprodil but adopting a remarkably different binding mode involving a distinct subcavity and receptor interactions |
|
| DCC2035 | Evt-201 | Novel partial positive allosteric GABAA receptor modulator |
|
| DCC2036 | Ew-7203 | Novel ALK5 inhibitor |
|
| DCC2037 | Ex4-dnp Conjugate 7 | Novel glucagon-like peptide 1 (GLP-1) receptor agonist, displaying significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies |
|
| DCC2038 | Ex-527(r) | Potent and selective SIRT1 inhibitor |
|
| DCC2039 | Ex-527(s) | Potent and selective SIRT1 inhibitor |
|
| DCC2040 | Exatecan Mesylate Dihydrate | Topoisomerase I inhibitor |
|
| DCC2041 | exosensor 517 | Novel Dual-Analyte Fluorescent Chemosensor for Visualizing Neurotransmitter Exocytosis |
|
| DCC2042 | Ex-tbdps-chc | Novel potent MCT1 inhibitor, exhibiting good single agent anticancer efficacy properties |
|
| DCC2043 | Ezn-2208 | Polyethylene glycol conjugate of SN38, acting as a topoisomerase I inhibitor,, exerting significant anti-leukaemia activity, overcoming ABCG2-mediated topotecan resistance |
|
| DCC2044 | F0045(s) | Novel influenza A hemagglutinin (HA) fusion inhibitor (EC 50 = 1.9 ± 0.3 μM), preventing HA from transitioning to the postfusion state at pH 5.0 |
|
| DCC2045 | F0371-0041 | Novel antifungal agent against Candida albicans persister cells |
|
